Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price
Objective This study analyzes the development, benefits, trial evidence, and price of new breast cancer drugs with US Food and Drug Administration (FDA) approval. Methods We identified 26 drugs with 42 FDA-approved indications for early and metastatic breast cancer (2000-2023). Data were collected f...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 2024
|
| In: |
Breast cancer
Year: 2024, Volume: 31, Issue: 6, Pages: 1144-1155 |
| ISSN: | 1880-4233 |
| DOI: | 10.1007/s12282-024-01634-x |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s12282-024-01634-x Verlag, kostenfrei, Volltext: http://link.springer.com/article/10.1007/s12282-024-01634-x 
|
| Author Notes: | Julia Caroline Michaeli, Thomas Michaeli, Dario Trapani, Sebastian Albers, Dominik Dannehl, Rachel Würstlein, Daniel Tobias Michaeli |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1915217539 | ||
| 003 | DE-627 | ||
| 005 | 20250716223453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250121s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12282-024-01634-x |2 doi | |
| 035 | |a (DE-627)1915217539 | ||
| 035 | |a (DE-599)KXP1915217539 | ||
| 035 | |a (OCoLC)1528016852 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Michaeli, Julia |d 1996- |e VerfasserIn |0 (DE-588)127911424X |0 (DE-627)1832296377 |4 aut | |
| 245 | 1 | 0 | |a Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price |c Julia Caroline Michaeli, Thomas Michaeli, Dario Trapani, Sebastian Albers, Dominik Dannehl, Rachel Würstlein, Daniel Tobias Michaeli |
| 264 | 1 | |c November 2024 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 25. September 2024 | ||
| 500 | |a Gesehen am 21.01.2025 | ||
| 520 | |a Objective This study analyzes the development, benefits, trial evidence, and price of new breast cancer drugs with US Food and Drug Administration (FDA) approval. Methods We identified 26 drugs with 42 FDA-approved indications for early and metastatic breast cancer (2000-2023). Data were collected from FDA labels, clinicaltrials.gov, and Medicare and Medicaid. Overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) and tumor response’s relative risk (RR) alongside objective response rate (ORR) were meta-analyzed. Results The median development time for breast cancer drugs was 7.8 years (95% CI 6.2-10.8). 26% of treatments were considered innovative (“first-in-indication”) with 88% acting via a targeted mechanism. 64% were small molecules, 19% antibodies, and 18% antibody-drug conjugates. 38% were approved for HR + and 31% for HER2 + breast cancer. 6 indications were for early and 36 for metastatic breast cancer. Indications utilized FDA’s special programs: orphan (2%), fast track (24%), accelerated approval (19%), priority review (74%), breakthrough therapy (44%). Approval was predominantly supported by phase 3 trials (88%) of randomized controlled design (66%), enrolling a median of 585 patients (IQR 417-752) at 181 centers (IQR 142-223) across 19 countries (IQR 17-20). New drugs’ HR were 0.78 for OS (95% CI 0.74-0.82) and 0.59 for PFS (95% CI 0.54-0.64) with a RR for tumor response of 1.61 (95% CI 1.46-1.76). Median improvements of OS were 2.8 months (IQR 1.8-5.8) and PFS were 4.4 months (IQR 2.2-7.1). In single-arm trials, the average ORR was 31% (95% CI 10-53). In meta-regressions, the correlation between OS/PFS was 0.34 (p = 0.031) and OS/response was 0.01 (p = 0.435). 60% of treatments had a ‘high-value’ ESMO-MCBS score with 14% demonstrating improvements in quality of life. The median price was $16,013 per month (95% CI 13,097-17,617). There was no association between prices and patient benefit. The median value per life year gained was $62,419 (IQR 25,840-86,062). Conclusions Over the past two decades, the development of innovative and effective drugs transformed the treatment landscape for breast cancer patients. Yet, investigators and regulators must safeguard that highly-priced new drugs demonstrate improvements in patient-centered clinical endpoints: overall survival and quality of life. | ||
| 700 | 1 | |a Michaeli, Christoph T. |d 1992- |e VerfasserIn |0 (DE-588)1277182337 |0 (DE-627)1830343769 |4 aut | |
| 700 | 1 | |a Trapani, Dario |e VerfasserIn |4 aut | |
| 700 | 1 | |a Albers, Sebastian |d 1991- |e VerfasserIn |0 (DE-588)1258831201 |0 (DE-627)1805362208 |4 aut | |
| 700 | 1 | |a Dannehl, Dominik |d 1994- |e VerfasserIn |0 (DE-588)119681452X |0 (DE-627)167864059X |4 aut | |
| 700 | 1 | |a Würstlein, Rachel |d 1971- |e VerfasserIn |0 (DE-588)122386175 |0 (DE-627)70588886X |0 (DE-576)293248400 |4 aut | |
| 700 | 1 | |a Michaeli, Daniel |d 1997- |e VerfasserIn |0 (DE-588)1277183244 |0 (DE-627)1830345109 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer |d Berlin : Springer, 1994 |g 31(2024), 6 vom: Nov., Seite 1144-1155 |h Online-Ressource |w (DE-627)548636184 |w (DE-600)2394259-9 |w (DE-576)281357080 |x 1880-4233 |7 nnas |a Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:6 |g month:11 |g pages:1144-1155 |g extent:12 |a Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s12282-024-01634-x |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://link.springer.com/article/10.1007/s12282-024-01634-x |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250121 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1277183244 |a Michaeli, Daniel |m 1277183244:Michaeli, Daniel |d 910000 |d 910100 |e 910000PM1277183244 |e 910100PM1277183244 |k 0/910000/ |k 1/910000/910100/ |p 7 |y j | ||
| 998 | |g 1277182337 |a Michaeli, Christoph T. |m 1277182337:Michaeli, Christoph T. |d 60000 |d 63600 |d 60000 |e 60000PM1277182337 |e 63600PM1277182337 |e 60000PM1277182337 |k 0/60000/ |k 1/60000/63600/ |k 0/60000/ |p 2 | ||
| 999 | |a KXP-PPN1915217539 |e 4654704558 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Julia","display":"Michaeli, Julia","family":"Michaeli"},{"given":"Christoph T.","role":"aut","family":"Michaeli","display":"Michaeli, Christoph T."},{"given":"Dario","role":"aut","display":"Trapani, Dario","family":"Trapani"},{"given":"Sebastian","role":"aut","display":"Albers, Sebastian","family":"Albers"},{"role":"aut","given":"Dominik","family":"Dannehl","display":"Dannehl, Dominik"},{"given":"Rachel","role":"aut","display":"Würstlein, Rachel","family":"Würstlein"},{"role":"aut","given":"Daniel","display":"Michaeli, Daniel","family":"Michaeli"}],"note":["Online veröffentlicht: 25. September 2024","Gesehen am 21.01.2025"],"title":[{"title_sort":"Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price","title":"Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price"}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"November 2024"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Julia Caroline Michaeli, Thomas Michaeli, Dario Trapani, Sebastian Albers, Dominik Dannehl, Rachel Würstlein, Daniel Tobias Michaeli"]},"recId":"1915217539","id":{"eki":["1915217539"],"doi":["10.1007/s12282-024-01634-x"]},"relHost":[{"language":["eng"],"note":["Gesehen am 08.11.13"],"title":[{"title":"Breast cancer","title_sort":"Breast cancer","subtitle":"the journal of the Japanese Breast Cancer Society"}],"origin":[{"dateIssuedDisp":"1994-","publisherPlace":"Berlin ; Tokyo","publisher":"Springer ; Japanese Breast Cancer Soc.","dateIssuedKey":"1994"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"issue":"6","year":"2024","pages":"1144-1155","text":"31(2024), 6 vom: Nov., Seite 1144-1155","extent":"12","volume":"31"},"disp":"Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and priceBreast cancer","id":{"zdb":["2394259-9"],"eki":["548636184"],"issn":["1880-4233"]},"pubHistory":["1.1994 -"],"recId":"548636184","physDesc":[{"extent":"Online-Ressource"}]}]} | ||
| SRT | |a MICHAELIJUBREASTCANC2024 | ||